secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001326190-24-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set
--------------------------------------------------------------------------

- Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.
- Cash, equivalents and short-term investments total $139.4M as of Sept 30, 2024.
- Completed enrollment in Phase 2b IMPACT trial for MASH; top-line data expected Q2 2025.
- FDA agreed on Phase 3 obesity program design; IND submissions for up to three additional indications planned.
- Appointed Greg Weaver as CFO on November 11, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/0001326190-24-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/alt-20241112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer